Pernio and early SARS-CoV-2 variants: natural history of a prospective cohort and the role of interferon

Ashley T Ng; John J Moon; Olivia R Steidl; Hailey Bussan; Jennifer M Tran; George Luong; Aman Nihal; Meaghan Kenfield; Justin Frere; Benjamin R TenOever; Ana C Costa da Silva; Jacqueline W Mays; Edward W Cowen; Beth A Drolet; Anne Marie Singh; Lisa M Arkin

doi:10.1111/bjd.21693

Pernio and early SARS-CoV-2 variants: natural history of a prospective cohort and the role of interferon

Br J Dermatol. 2022 Oct;187(4):617-619. doi: 10.1111/bjd.21693. Epub 2022 Jul 6.

Authors

Affiliations

¹ Department of Dermatology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
² Division of Allergy & Immunology, Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
³ Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
⁴ Department of Microbiology, New York University, Langone Health, New York, NY, 10016, USA.
⁵ Oral Immunobiology Unit, NIDCR, NIH, Bethesda, MD, USA.
⁶ Dermatology Branch, NIAMS, NIH, Bethesda, MD, USA.

Abstract

Cases of new-onset pernio and recurrences in our cohort align tightly with trends in mean 7-day COVID-19 positivity in Wisconsin and mean temperature in Madison, Wisconsin by month.

Publication types

Letter

MeSH terms

Antiviral Agents
COVID-19*
Chilblains* / diagnosis
Chilblains* / epidemiology
Chilblains* / genetics
Humans
Interferons
Prospective Studies
SARS-CoV-2 / genetics

Substances

Antiviral Agents
Interferons

Supplementary concepts

SARS-CoV-2 variants

Grants and funding

ZIA DE000747/ImNIH/Intramural NIH HHS/United States